BDSI insider filings
BIODELIVERY SCIENCES INTERNATIONAL INC — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-03-22. Screen BDSI transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BDSI between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — BIODELIVERY SCIENCES INTERNATIONAL INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2022-03-22 | 4 | Watson W. Mark — Director | Other (J): 90,663 @ $0 · Disposition to issuer (D): 22,685 (derivative) @ $0 · Disposition to issuer (D): 54,740 (derivative) @ $0 · Disposition to issuer (D): 85,760 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Vollins James — See Remarks | Disposition to issuer (D): 91,401 (derivative) @ $0 · Disposition to issuer (D): 29,826 (derivative) @ $0 · Disposition to issuer (D): 43,334 (derivative) @ $0 · Disposition to issuer (D): 269,244 (derivative) @ $0 · Disposition to issuer (D): 82,508 (derivative) @ $0 · Disposition to issuer (D): 282,055 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Singh Vanila — Director | Other (J): 35,851 @ $0 · Disposition to issuer (D): 17,019 (derivative) @ $0 · Disposition to issuer (D): 81,008 (derivative) @ $0 · Disposition to issuer (D): 48,000 (derivative) @ $0 · Disposition to issuer (D): 85,760 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Smith Thomas B — Chief Medical Officer | Other (J): 52,530 @ $0 · Disposition to issuer (D): 88,719 (derivative) @ $0 · Disposition to issuer (D): 117,691 (derivative) @ $0 · Disposition to issuer (D): 130,000 (derivative) @ $0 · Disposition to issuer (D): 287,194 (derivative) @ $0 · Disposition to issuer (D): 259,186 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Sirgo Mark A — Director | Other (J): 1,166,866 @ $0 · Disposition to issuer (D): 11,685 (derivative) @ $0 · Disposition to issuer (D): 22,500 (derivative) @ $0 · Disposition to issuer (D): 48,000 (derivative) @ $0 · Disposition to issuer (D): 48,000 (derivative) @ $0 · Disposition to issuer (D): 85,760 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Plesha Scott M. — See Remarks | Other (J): 345,127 @ $0 · Disposition to issuer (D): 119,228 (derivative) @ $0 · Disposition to issuer (D): 245,000 (derivative) @ $0 · Disposition to issuer (D): 348,222 (derivative) @ $0 · Disposition to issuer (D): 369,721 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Other (J): 7,588,395 @ $0 · Disposition to issuer (D): 22,685 (derivative) @ $0 · Disposition to issuer (D): 7,500 (derivative) @ $0 · Disposition to issuer (D): 85,760 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Golubieski John — See Remarks | Disposition to issuer (D): 126,199 (derivative) @ $0 · Disposition to issuer (D): 333,133 (derivative) @ $0 · Disposition to issuer (D): 373,533 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Greenleaf Peter — Director | Other (J): 105,034 @ $0 · Disposition to issuer (D): 27,746 (derivative) @ $0 · Disposition to issuer (D): 64,164 (derivative) @ $0 · Disposition to issuer (D): 114,347 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Davis Todd C — Director | Other (J): 252,207 @ $0 · Disposition to issuer (D): 22,685 (derivative) @ $0 · Disposition to issuer (D): 48,123 (derivative) @ $0 · Disposition to issuer (D): 85,760 (derivative) @ $0 | EDGAR |
| 2022-03-22 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Other (J): 105,133 @ $0 · Disposition to issuer (D): 316,919 (derivative) @ $0 · Disposition to issuer (D): 96,000 (derivative) @ $0 · Disposition to issuer (D): 160,000 (derivative) @ $0 · Disposition to issuer (D): 66,805 (derivative) @ $0 · Disposition to issuer (D): 840,000 (derivative) @ $0 · +1 more | EDGAR |
| 2022-03-11 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Option exercise (M): 5,333 @ $0 · Option exercise (M): 5,333 (derivative) @ $0 | EDGAR |
| 2022-02-15 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Conversion (C): 2,422,222 @ $1.80 · Conversion (C): 436 (derivative) @ $10,000 | EDGAR |
| 2022-02-08 | 4 | Vollins James — See Remarks | Sale (S): 18,541 @ $3.60 · Tax withholding (F): 9,872 @ $3.66 | EDGAR |
| 2022-02-01 | 4 | Davis Todd C — Director | Option exercise (M): 7,684 @ $0 · Grant/award (A): 85,760 (derivative) @ $3.66 · Grant/award (A): 15,369 (derivative) @ $0 · Option exercise (M): 7,684 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Plesha Scott M. — See Remarks | Option exercise (M): 21,050 @ $0 · Option exercise (M): 10,869 @ $0 · Option exercise (M): 13,334 @ $0 · Grant/award (A): 369,721 (derivative) @ $3.66 · Grant/award (A): 66,257 (derivative) @ $0 · Option exercise (M): 21,050 (derivative) @ $0 · +2 more | EDGAR |
| 2022-01-31 | 4 | Watson W. Mark — Director | Option exercise (M): 7,684 @ $0 · Grant/award (A): 85,760 (derivative) @ $3.66 · Grant/award (A): 15,369 (derivative) @ $0 · Option exercise (M): 7,684 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Singh Vanila — Director | Option exercise (M): 7,684 @ $0 · Grant/award (A): 85,760 (derivative) @ $0 · Grant/award (A): 15,369 (derivative) @ $0 · Option exercise (M): 7,684 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Sirgo Mark A — Director | Option exercise (M): 7,684 @ $0 · Grant/award (A): 85,760 (derivative) @ $0 · Grant/award (A): 15,369 (derivative) @ $0 · Option exercise (M): 7,684 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Option exercise (M): 7,684 @ $0 · Grant/award (A): 85,760 (derivative) @ $0 · Grant/award (A): 15,369 (derivative) @ $0 · Option exercise (M): 7,684 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Greenleaf Peter — Director | Option exercise (M): 10,246 @ $0 · Grant/award (A): 114,347 (derivative) @ $3.66 · Grant/award (A): 20,492 (derivative) @ $0 · Option exercise (M): 10,246 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Grant/award (A): 1,143,467 (derivative) @ $3.66 · Grant/award (A): 204,918 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Golubieski John — See Remarks | Grant/award (A): 373,533 (derivative) @ $3.66 · Grant/award (A): 66,940 (derivative) @ $0 | EDGAR |
| 2022-01-31 | 4 | Smith Thomas B — Chief Medical Officer | Option exercise (M): 17,361 @ $0 · Option exercise (M): 7,548 @ $0 · Option exercise (M): 7,667 @ $0 · Grant/award (A): 259,186 (derivative) @ $3.66 · Grant/award (A): 46,448 (derivative) @ $0 · Option exercise (M): 17,361 (derivative) @ $0 · +2 more | EDGAR |
| 2022-01-31 | 4 | Vollins James — See Remarks | Option exercise (M): 16,276 @ $0 · Option exercise (M): 8,303 @ $0 · Option exercise (M): 3,834 @ $0 · Grant/award (A): 282,055 (derivative) @ $0 · Grant/award (A): 50,546 (derivative) @ $0 · Option exercise (M): 16,276 (derivative) @ $0 · +2 more | EDGAR |
| 2022-01-19 | 4 | Vollins James — See Remarks | Grant/award (A): 82,508 (derivative) @ $3.03 | EDGAR |
| 2021-12-06 | 4 | Sirgo Mark A — Director | Purchase (P): 18,587 @ $2.69 | EDGAR |
| 2021-11-23 | 4 | Singh Vanila — Director | Option exercise (M): 5,333 @ $0 · Option exercise (M): 5,333 (derivative) @ $0 | EDGAR |
| 2021-11-22 | 4 | KOTLER KEVIN — Director Broadfin Healthcare Master Fund Ltd — Director Broadfin Capital, LLC — Director | Purchase (P): 100,000 @ $3.06 | EDGAR |
| 2021-11-19 | 4 | Sirgo Mark A — Director | Sale (S): 10,000 @ $3.04 | EDGAR |
| 2021-11-19 | 4/A | Sirgo Mark A — Director | Purchase (P): 10,000 @ $3.04 | EDGAR |
| 2021-11-15 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Purchase (P): 100,000 @ $3.20 | EDGAR |
| 2021-11-12 | 4 | Sirgo Mark A — Director | Purchase (P): 16,000 @ $3.20 | EDGAR |
| 2021-11-09 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Purchase (P): 257,800 @ $3.47 | EDGAR |
| 2021-11-08 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Option exercise (M): 53,333 @ $0 · Option exercise (M): 53,333 (derivative) @ $0 | EDGAR |
| 2021-08-25 | 4 | Singh Vanila — Director | Option exercise (M): 4,000 @ $0 · Grant/award (A): 48,000 (derivative) @ $3.76 · Grant/award (A): 8,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2021-08-25 | 4 | Sirgo Mark A — Director | Option exercise (M): 4,000 @ $0 · Grant/award (A): 48,000 (derivative) @ $3.76 · Grant/award (A): 8,000 (derivative) @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | Singh Vanila — Director | Option exercise (M): 6,750 @ $0 · Option exercise (M): 6,750 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | Sirgo Mark A — Director | Option exercise (M): 4,000 @ $0 · Option exercise (M): 4,000 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Option exercise (M): 5,567 @ $0 · Option exercise (M): 5,567 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | Watson W. Mark — Director | Option exercise (M): 30,000 @ $0 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Option exercise (M): 30,000 @ $0 · Option exercise (M): 15,000 @ $2.93 · Option exercise (M): 30,000 (derivative) @ $0 · Conversion (C): 15,000 (derivative) @ $2.93 | EDGAR |
| 2021-08-10 | 4 | Greenleaf Peter — Director | Option exercise (M): 35,000 @ $0 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2021-08-10 | 4 | Davis Todd C — Director | Option exercise (M): 30,000 @ $0 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | KOTLER KEVIN — Director Broadfin Capital, LLC — Director Broadfin Healthcare Master Fund Ltd — Director | Purchase (P): 150,000 @ $3.16 · Purchase (P): 100,000 @ $3.24 · Purchase (P): 50,000 @ $3.25 | EDGAR |
| 2021-05-13 | 4 | Sirgo Mark A — Director | Purchase (P): 7,500 @ $3.16 · Purchase (P): 5,000 @ $3.24 · Purchase (P): 3,000 @ $3.16 | EDGAR |
| 2021-03-16 | 4 | Plesha Scott M. — See Remarks | Grant/award (A): 20,834 @ $0 · Option exercise (M): 20,834 @ $0 · Option exercise (M): 20,834 (derivative) @ $0 | EDGAR |
| 2021-03-11 | 4 | Bailey Jeffrey Allen — Chief Executive Officer, Director | Option exercise (M): 5,333 @ $0 · Option exercise (M): 5,333 (derivative) @ $0 | EDGAR |
| 2021-02-08 | 4 | Vollins James — See Remarks | Sale (S): 8,303 @ $3.97 · Sale (S): 3,833 @ $4.16 | EDGAR |
| 2021-02-02 | 4 | Vollins James — See Remarks | Option exercise (M): 8,303 @ $0 · Option exercise (M): 3,833 @ $0 · Option exercise (M): 8,303 (derivative) @ $0 · Option exercise (M): 3,833 (derivative) @ $0 | EDGAR |
Recent 8-K events — BIODELIVERY SCIENCES INTERNATIONAL INC
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2022-03-22 | 8-K | 1.02 — Termination of a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-02-15 | 8-K/A | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-02-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2022-01-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-12-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-11-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-09-27 | 8-K | 8.01 — Other Events | EDGAR |
| 2021-09-21 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2021-09-09 | 8-K | 8.01 — Other Events | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BDSI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs